Aligning Policy with Practice: What Providers Need from Payers in Retinal Disease Management

Learn About:

1. The role of payers in preventing blindness from DR/DME and AMD
2. The successful implementation of payer best practice strategies in DR/DME and AMD to improve patient outcomes
3. Current strategies and gaps in the prevention and treatment of vision loss due to DR/DME and AMD

Expert Faculty Presenters

Michael Shannon, MD Endocrinologist Summit Pacific Medical Center Medical Director Ventegra Click here for biography Mark Barakat, MD Director of Research Retina Macula Institute of Arizona Medical Director Spectra Eye Institute Click here for biography

Target Audience
This activity is designed to meet the educational needs of managed care pharmacy directors, registered nurses, clinical pharmacists, quality directors and medical directors.

Statement of Need/Program Overview
Within the space of just a few years, several new retinal treatments have been approved promising increased durability and better patient outcomes. These conditions can significantly impact vision and quality of life for patients. This webcast will explore how clinical realities intersect with coverage policies in the management of diabetic retinopathy (DR), diabetic macular edema (DME), and age related macular degeneration (AMD). This session will highlight current practice patterns, gaps in care, and the unmet needs providers face when navigating treatment decisions for patients at risk of vision loss. Our experts will share candid perspectives on where payer policies support—or hinder—optimal outcomes, and outline practical, evidence aligned strategies payers can adopt to better enable timely, effective care. Attendees will gain a clearer understanding of the shared challenges across stakeholders and learn how collaborative best practices can improve patient outcomes in both DR/DME and AMD.

Educational Objectives
After completing this activity, the participant should be better able to:

• Explain health care providers’ and payers’ perspectives on current strategies and gaps in the prevention and treatment of vision loss due to DR/DME and AMD
• Illustrate the role of payers in preventing blindness from DR/DME and AMD, including their views on coverage policies, care coordination, and opportunities for system-level interventions
• Outline the successful implementation of payer best practice strategies in DR/DME and AMD to improve patient outcomes

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates these live activities for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates these continuing education activities for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: Coming Soon
Activity Type: Knowledge-based

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
Medical Education Resources designates these live activities for a maximum of 0.5 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 0.5 contact hour.

DISCLOSURE OF FINANCIAL INTEREST
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company. The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Regeneron Pharmaceuticals, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

FEE INFORMATION
There is no fee for this educational activity.